Affimed NV represents a company philosophy rooted in innovative biotechnological solutions. Their core values include a commitment to advancing patient care through cutting-edge research and development. Affimed NV aims to revolutionize the treatment landscape by pioneering novel, targeted immunotherapies. With a focus on engaging the power of the innate immune system, Affimed NV is dedicated to harnessing the potential of natural killer cells and other immune cells to combat various cancers effectively. By leveraging their expertise in innate immunity and deep-rooted commitment to scientific excellence, Affimed NV strives to make a transformative impact on patient outcomes and revolutionize the field of cancer treatment.

Affimed NV is primarily present in various countries and regions around the world. The company has established a global presence, with key markets in the United States, Europe, and Asia. Affimed NV operates in several countries within these regions, including the United States, Germany, Switzerland, and Japan. By strategically expanding its operations, Affimed NV aims to reach a broad customer base and maximize its market potential.

Affimed NV has achieved several significant milestones in its history. The company successfully completed its initial public offering (IPO) in 2014, raising funds to support its research and development efforts. In 2017, Affimed NV entered into a strategic collaboration with Genentech, a leading biotechnology company, to develop and commercialize novel immunotherapies for multiple cancer indications. This collaboration validates the potential of Affimed's innovative platform technology. Furthermore, in 2020, the company initiated clinical trials for its lead product candidate, AFM13, a CD30/CD16A-targeting tetravalent bispecific antibody, showing promising results for cancer treatment. These achievements demonstrate Affimed NV's commitment to advancing novel therapies and its potential for growth in the biotech industry.

Affimed NV is a biopharmaceutical company headquartered in Heidelberg, Germany. Founded in 2000, Affimed is focused on developing innovative immunotherapies for cancer treatment and has a rich history in the field. The company specializes in generating and engineering targeted immune cell proteins called bispecific antibodies. Affimed's dedication to scientific excellence and cutting-edge research has enabled them to create a robust pipeline of potential therapies. With collaborations and partnerships in the industry, Affimed NV continues to strive towards providing novel and effective treatment options for patients battling various types of cancer.

The main competitors of Affimed NV in the market include companies such as Merck & Co., Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Novartis International AG.

Affimed NV is primarily active in the biotechnology industry.

The business model of Affimed NV is focused on the development of next-generation immunotherapies for cancer treatment. Affimed NV utilizes its proprietary technology platform, called Redirected Optimized Cell Killing (ROCK®), to engineer and develop innovative antibody-based therapeutics. Through the ROCK® platform, Affimed NV develops bispecific antibodies that can bind to both cancer cells and immune cells, activating the immune system to target and eliminate cancer cells. This targeted approach aims to enhance the effectiveness and safety of cancer treatment. As a leading biopharmaceutical company, Affimed NV is dedicated to advancing the field of immuno-oncology and improving patient outcomes.

Affimed KGV ir -0,54.

Affimed KUV ir 6,35.

AlleAktien kvalitātes vērtējums Affimed ir 4/10.

gaidāmā Affimed apgrozījums ir 4,77 milj. EUR.

gaidāmā Affimed peļņa ir -56,42 milj. EUR.

Affimed NV is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of cancer and other serious diseases. The company is headquartered in Heidelberg, Germany, and also operates offices in the United States. Affimed's business model is based on the discovery and development of novel therapeutic antibodies designed to specifically recognize and attack cancer cells. The company utilizes its proprietary technology platform, known as "Redirected Optimized Cell Killing" (ROCK), to achieve high precision in the identification and targeting of cancer cells. Affimed's products are divided into various categories, including clinical pipeline products, platform technology, and partner programs. The company's strategy focuses on developing novel immunotherapies for cancer patients and marketing them globally through a combination of internal pipeline development, strategic partnerships, and platform technologies.

Affimed izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Affimed vai uzņēmums nedod dividendes.

Affimed ISIN ir NL0010872420.

Affimed WKN ir A12BHU.

Affimed simbols ir AFMD.

Pēdējo 12 mēnešu laikā Affimed maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Affimed plāno maksāt dividendes 0 EUR apmērā.

Affimed pašreizējā dividendu rentabilitāte ir .

Affimed maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Affimed pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Affimed tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Affimed apmērā 0 EUR, kas tika izmaksāta 17.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.12.2024..

Pēdējās dividendes izmaksa notika 17.12.2024..

Gadā 2023, Affimed izmaksāja 0 EUR dividendes.

Affimed dividendes tiek izmaksātas EUR.